Ambrisentan, also known as BSF-208075 and LU-208075, is a drug indicated for use in the treatment of pulmonary hypertension. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan significantly improved exercise capacity (6-minute walk distance) compared with placebo in two double-blind, multicenter trials (ARIES-1 and ARIES-2). Ambrisentan was approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency, and designated an orphan drug, for the treatment of pulmonary hypertension.
Properties:
Density: 1.228g/cm3
Boiling Point: 551.1ºC at 760mmHg
Flash Point: 287.1ºC
Refractive Index: 1.593
Vapor Pressure: 5.56E-13mmHg at 25°C
Endothelin Receptor Inhibitors Related Prodcuts: